Sign in

CIK 0001799448

  • Non-accelerated filer
  • Smaller reporting company

Aligos Therapeutics, Inc.

Sign in to watch
Ticker
ALGS
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
Phone
+1 800-466-6059
Business address
ONE CORPORATE DR., 2ND FLOOR, SOUTH SAN FRANCISCO, CA, 94080
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$0
in 0 filings

Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Date Insider Transaction Shares Price Value Owned after
2024-03-01 McClure Matthew W. Chief Medical Officer Grant or award · Stock Option (Right to Buy) +72,000 72,000
2024-02-28 McClure Matthew W. Chief Medical Officer Grant or award · Stock Option (Right to Buy) +75,183 75,183
2024-02-28 McClure Matthew W. Chief Medical Officer Grant or award · Stock Option (Right to Buy) +65,713 65,713
2024-02-28 McClure Matthew W. Chief Medical Officer Grant or award · Stock Option (Right to Buy) +16,428 16,428
2024-02-27 McClure Matthew W. Chief Medical Officer Returned to the company · Stock Option (Right to Buy) −255,626 0
2024-02-27 McClure Matthew W. Chief Medical Officer Returned to the company · Stock Option (Right to Buy) −92,000 0
2024-02-27 McClure Matthew W. Chief Medical Officer Returned to the company · Stock Option (Right to Buy) −23,000 0
2023-09-08 McClure Matthew W. Chief Medical Officer Grant or award · Stock Option (Right to Buy) +48,000 48,000
2023-03-15 McClure Matthew W. Chief Medical Officer Grant or award · Stock Option (Right to Buy) +75,000 75,000
2022-07-07 McClure Matthew W. Chief Medical Officer Grant or award · Stock Option (Right to Buy) +46,000 46,000

Page 1 of 1 · 10 trades